Search for the biomarker of the immune checkpoint inhibitor

2019 Fiscal Year Final Research Report

• Project/Area Number: 17K10780
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory surgery
• Research Institution: Shiga University of Medical Science
• Principal Investigator: Igarashi Tomoyuki 滋賀医科大学, 医学部, 非常勤講師 (00510314)
• Co-Investigator(Kenkyū-buntansha): 花岡 淳 滋賀医科大学, 医学部, 准教授 (00452243) ; 寺本 晃治 滋賀医科大学, 医学部, 特任講師 (10452244)
• Project Period (FY): 2017-04-01 – 2020-03-31
• Keywords: 非小細胞がん / PD-L1 / がん関連線維芽細胞 / 無再発生存期間

Outline of Final Research Achievements

The expression of PD-L1 molecules in non-small cell lung cancer was reversibly controled by IFN γ. Furthermore, PD-L1 molecules overexpression in early non-small cell lung cancer means prolong relapse free survival, but in an advanced stage, it means shorten relapse free survival adversely. We showed the possibility that plasma PD-L1 molecules were influenced not only PD-L1 expression on lung cancer cells but also the tumor infitrated macrophages. PD-L1 overexpression of cancer-asociated fibroblasts means prolong relapse free survival and it was the independent convalescence marker for convalescence predictions.

Free Research Field

肺がん

Academic Significance and Societal Importance of the Research Achievements

非小細胞肺がんにおいて、免疫チェックポイント阻害薬を用いて治療を行う際の、治療効果予測のためのバイオマーカーを探索し、非小細胞肺がんにおけるPD-L1発現の臨床病理学的な意義について示した。